药物重定位:学术研究者的误解、挑战与机遇
本文讨论药物重定位在学术研究中常被忽视的关键因素,包括财务与知识产权考量、临床与监管路径以及临床均衡。作者指出药物重定位的目标是获得监管机构批准的新适应症标签,其路径与传统药物开发相似,学术研究者需更好识别重定位机会。
要点
- 药物重定位需考虑财务与知识产权、临床与监管路径及临床均衡。
- 重定位目标为获得监管批准的新适应症标签,路径与传统开发相似。
- 学术研究者常忽视上述过程,导致重定位未能兑现承诺。
核心结论
- 学术研究者对药物重定位所需过程考虑不足,可能是其未能兑现承诺的原因。
主要发现
- 药物重定位常被宣传为成本和时间有效的提供新药机制。
- 常被忽视的方面包括财务与知识产权考量、临床与监管路径以及临床均衡。
- 临床均衡为随机对照试验提供伦理依据。
- 药物重定位的目标是获得监管机构批准的现有药物新标签。
- 药物重定位的轨迹与传统药物开发相似。
临床怎么用
- 学术研究者在识别药物重定位机会时应考虑财务与知识产权、临床与监管路径及临床均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often, however, there is insufficient consideration by academic researchers of the processes required to ensure that a repurposed drug can be used for a new indication. This may explain the inability of drug repurposing to fulfill its promise. Important aspects, often overlooked, include financial and intellectual property considerations, the clinical and regulatory path, and clinical equipoise, which provides ethical justification for randomized controlled trials. The goal of drug repurposing is to obtain a new regulator-approved label for an existing drug, and so, the trajectory for drug repurposing and traditional drug development is similar. Here, we discuss factors critical for a successful repurposed medicine to help academic investigators better identify drug repurposing opportunities.
引用
- Begley CG, Ashton M, Baell J, et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021. PMID: 34550729. doi:10.1126/scitranslmed.abd5524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。